Hanzhang Lu1, Min Sheng2, Peiying Liu1, Harshan Ravi1, Shin-Lei Peng1, Ramon Diaz-Arrastia3, Michael D. Devous Sr.4, and Kyle B. Womack5
1Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 4Avid Radiopharmaceuticals, Inc., Philadelphia, PA, United States, 5Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, United States
Synopsis
Alzheimer’s
disease (AD) is the leading cause of degenerative dementia in the aging
population. Patients with AD have alterations in cerebral hemodynamic function.
Therefore, improved cerebrovascular function may be an attractive goal for
pharmaceutical intervention in AD. Our study applied several novel non-invasive
MRI techniques to investigate the alterations of CBF, cerebral metabolic rate
of oxygen (CMRO2) and cerebrovascular reactivity (CVR) after a single dose of
sildenafil administration in order to assess its physiological effects in AD
patients. Our data suggest that a single dose of sildenafil improves cerebral
hemodynamic function and increases cerebral oxygen metabolism in patients with
AD.Purpose
While
amyloid-centered etiology remains the leading hypothesis in Alzheimer’s disease
(AD), experimental therapies targeting A-beta have been disappointing.
Therefore, in recent years, improved cerebrovascular function has become an
attractive goal for intervention in AD. Sildenafil, sold under the trademark
Viagra, is an inhibitor of cGMP-specific phosphodiesterase and enhances nitric
oxide (NO)-mediated vasodilatation. In animal studies, after treatment for 3
weeks, sildenafil has been shown to rescue the memory deficits of transgenic
mouse models of AD (1). However, sildenafil has not been investigated in AD patients.
The goal of this study is to obtain evidence that a single dose of sildenafil
improves cerebral hemodynamic dysfunction in patients with AD.
Methods
Participants
A total of 14 early AD patients aged 62-87 years (Mean±SD
71.6±7.5) were studied on a 3T MRI (Philips). The study consisted of two
sessions. The first session started in the morning. Blood pressure was measured
before they entered into the MRI scanner room. Three brain physiological markers
were measured by advanced MRI techniques, including CBF, cerebral metabolic
rate of oxygen (CMRO2) and cerebrovascular reactivity (CVR) to CO2. After the
first session, participants were taken out of the magnet and given a single
50mg dose of sildenafil. One hour later, the second session started with
repeated measurement of CBF, CMRO2 and CVR. Blood pressure was measured one
more time before subjects entered into the scanner room.
MRI Experiment
CBF of the participant was assessed with two
different techniques. Global CBF was measured with a phase-contrast MRI
technique and regional CBF was measured with a Pseudo-Continuous Arterial Spin
Labeling (pCASL) technique. CMRO2 reflects the amount of oxygen consumed
by the brain. Global CMRO2 (in units of μmol O2/min/100 g brain tissue) was
quantified based on Fick principle of arteriovenous difference in oxygen
content, in which global CBF is already measured with phase-contrast as
described above and global venous oxygenation (Yv) was measured from the superior
sagittal sinus (SSS) using a novel T2-relaxation-under-spin-tagging (TRUST) MRI
(2) (Figure 1). CVR response to CO2 was measured using hypercapnia (5%
CO2 mixed with 21% O2 and 74% N2) challenge, in which the subjects breathed
hypercapnic gas and room air via a mouthpiece in an interleaved manner (50 seconds
CO2, 70 seconds room air, repeated four times), while BOLD images were acquired
continuously during the entire experimental period.
Statistical
Analysis
Global changes in CBF, CMRO2 and CVR between the
two time-points (before and after administration of sildenafil) were assessed
by paired t tests. Correlations between cognitive scores and the MRI markers
were assessed.
Results and Discussion
Participants’ demographic information in all experiments is
summarized in Table 1. Blood pressure between two time-points was unchanged.
We first examined whether the administration of sildenafil
altered blood supply to the brain. Global CBF as measured by PC-MRI was 55.3 ±
9.6 ml/100g/min (mean±SD) at the baseline and significantly increased (P=0.03)
to 59.0 ± 7.9 ml/100g/min after administration of sildenafil (Fig. 2A), an
increase of 7.9±12.8%. We then analyzed regional CBF maps measured with ASL MRI
to examine which brain region(s) manifests the most pronounced CBF enhancement.
Voxel-wise analyses suggested that increases in CBF were most significant in
bilateral medial temporal lobes (MTL) (Fig. 2B), an increase by 22.8% after
taking the drug.
Next, we examined whether the additional oxygen delivered
due to increased blood supply was actually taken up by the brain for its
oxidative metabolism. We observed that CMRO2 significantly increased by
5.1±7.9% (P=0.05) (Fig. 3A). Moreover, we found a significant correlation
(P=0.04) between baseline MoCA scores and CMRO2 alterations (Fig. 3B),
suggesting that physiological effects of sildenafil are more pronounced in
patients with more severe cognitive deficit (R=0.59, P=0.04).
CVR is another useful index of cerebral vascular
function. We found that whole-brain averaged CVR values showed a trend of lower
CVR after taking drugs (paired t test, one tail P=0.05). Voxel-wise comparison
revealed that CVR was significantly lower after administration of sildenafil in
several brain regions including precuneus, limbic lobe, temporal lobe, and
parietal lobe (Fig.4).
Conclusion
The
present study assessed brain blood supply and metabolism before and after a
single 50mg dose of sildenafil and revealed that sildenafil could improve CBF
and CMRO2 in AD patients, especially in the bilateral medial temporal lobes. Furthermore,
the enhancing effect seems to be more pronounced in patients with more severe
cognitive deficits.
Acknowledgements
NoneReferences
1) Puzzo et al. J of Neuroscience 29:8075 (2009);
2) Lu and Ge, MRM, 60:357 (2008).